Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jan-Mar;9(1):37-50.
doi: 10.1111/j.1582-4934.2005.tb00335.x.

Transplantation of hematopoietic stem cells from the peripheral blood

Jan Jansen  1 , Susan Hanks, James M Thompson, Michael J Dugan, Luke P Akard
Affiliations
Review

Transplantation of hematopoietic stem cells from the peripheral blood

Jan Jansen et al. J Cell Mol Med. 2005 Jan-Mar.

Abstract

Hematopoietic stem cells can be collected from the peripheral blood. These hematopoietic stem cells (HSC), or better progenitor cells, are mostly expressed as the percentage of cells than react with CD34 antibodies or that form colonies in semi-solid medium (CFU-GM). Under steady-state conditions the number of HSC is much lower in peripheral blood than in bone marrow. Mobilization with chemotherapy and/or growth factors may lead to a concentration of HSC in the peripheral blood that equals or exceeds the concentration in bone marrow. Transplantation of HSC from the peripheral blood results in faster hematologic recovery than HSC from bone marrow. This decreases the risk of infection and the need for blood-product support. For autologous stem-cell transplantation (SCT), the use of peripheral blood cells has completely replaced the use of bone marrow. For allogeneic SCT, on the other hand, the situation is more complex. Since peripheral blood contains more T-lymphocytes than bone marrow, the use of HSC from the peripheral blood increases the risk of graft-versus-host disease after allogeneic SCT. For patients with goodrisk leukemia, bone marrow is still preferred, but for patients with high-risk disease, peripheral blood SCT has become the therapy of choice.

PubMed Disclaimer

References

    1. Doss M.X., Koehler C.I., Gissel C., Hescheler J., Sachinidis A., Embryonic stem cells: a promising tool for cell replacement therapy, J. Cell. Mol. Med., 8:465–473, 2004. - PMC - PubMed
    1. Wakayama T., Tabar V., Rodigues I., Perry A.C.F., Studer L., Mombaerts P., Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer, Science, 292: 740–744, 2001. - PubMed
    1. Kocher A.A., Schuster M.D., Szabolcs M.J., Takuma S., Burkhoff D., Wang J., Homma S., Edwards N.M., Itescu S., Neovascularization of ischemic myocardium by human bone‐marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function, Nature Medicine, 7: 430–436, 2001. - PubMed
    1. Petersen B.E., Bowen W.C., Patrene K.D., Mars W.M., Sullivan A.K., Murase N., Boggs S.S., Greenberger J.S., Goff J.P., Bone marrow as a potential source of hepatic oval cells, Science, 284: 1168–1170, 1999. - PubMed
    1. Maximow A., Der Lymphozyt als gemeinsame Stammzelle der verschiedene Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Saugetiere, Folia Haematol. (Leipzig), 8; 125–141, 1909.

MeSH terms

Substances